Evidence map›Paper›PMID 39187209›Full record

ArticleNeurobiology of disease2024

Heterozygous loss of Engrailed-1 and α-synucleinopathy (En1/SYN): A dual-hit preclinical mouse model of Parkinson's disease, analyzed with artificial intelligence.

Lucas Stetzik, Gabriela Mercado, Jennifer A Steiner, Allison Lindquist, Carla Gilliland, Emily Schulz, Lindsay Meyerdirk, Lindsey Smith, Jeremy Molina, Darren J Moore

Abstract read
In one paragraph

Article in Neurobiology of disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lucas StetzikDepartment of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, United States. Electronic address: stetzik.lucas@gmail.com.
Gabriela MercadoDepartment of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, United States.
Jennifer A SteinerDepartment of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, United States.
Allison LindquistDepartment of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, United States.
Carla GillilandDepartment of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, United States.
Emily SchulzDepartment of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, United States.
Lindsay MeyerdirkDepartment of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, United States.
Lindsey SmithAiforia Inc, Cambridge Innovation Center, Cambridge, MA, United States.
Jeremy MolinaRush University Medical Center, Chicago, IL, United States.
Darren J MooreDepartment of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, United States.

Funding

Combining synucleinopathy and mitochondrial deficits in a novel mouse model of Parkinsons diseaseR21NS106078 · NINDS · VAN ANDEL RESEARCH INSTITUTE · PI BRUNDIN, PATRIK, KORDOWER, JEFFREY H · 2019 to 2020
$921k
Combining synucleinopathy and mitochondrial deficits in a novel mouse model of Parkinsons diseaseR33NS106078 · NINDS · VAN ANDEL RESEARCH INSTITUTE · PI KORDOWER, JEFFREY H, MOORE, DARREN JOHN · 2022 to 2022
$436k
NINDS NIH HHS R21 NS106078NINDS NIH HHS R33 NS106078
6 · The paper itself

Abstract

In this study, we develop and validate a new Parkinson's disease (PD) mouse model that can be used to better understand how the disease progresses and to test the effects of new, potentially disease-modifying, PD therapies. Our central hypothesis is that mitochondrial dysfunction intercalates with misfolded α-synuclein (α-syn) accumulation in a vicious cycle, leading to the loss of nigral neurons. Our hypothesis builds on the concept that PD involves multiple molecular insults, including mitochondrial dysfunction and aberrant α-syn handling. We predicted that mitochondrial deficits, due to heterozygous loss of Engrailed-1 (En1+/-), combined with bilateral injections of pathogenic α-syn fibrils (PFFs), will act to generate a highly relevant PD model - the En1/SYN model. Here, En1+/- mice received bilateral intrastriatal stereotaxic injections of either PBS or α-syn fibrils and were analyzed using automated behavioral tests and deep learning-assisted histological analysis at 2, 4, and 6 months post-injection. We observed significant and progressive Lewy body-like inclusion pathology in the amygdala, motor cortex, and cingulate cortex, as well as the loss of tyrosine hydroxylase-positive (TH+) cells in the substantia nigra. The En1/SYN model also exhibited significant motor impairments at 6 months post-injection, which were however not exacerbated as we had expected. Still, this model has a comprehensive number of PD-like phenotypes and is therefore superior when compared to the α-syn PFF or En1+/- models alone.

Indexed as

alpha-SynucleinHomeodomain ProteinsParkinson DiseaseAnimalsArtificial IntelligenceDisease Models, AnimalHeterozygoteMaleMiceMice, Inbred C57BLSubstantia NigraSynucleinopathiesalpha-SynucleinEn1 protein, mouseHomeodomain ProteinsAIAlpha synucleinBehaviorengrailed1Preclinical

Identifiers

PMID39187209
PMCPMC11513166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.